Romiti, Giulio Francesco http://orcid.org/0000-0002-3788-8942
Nabrdalik, Katarzyna
Corica, Bernadette
Bucci, Tommaso
Proietti, Marco
Qian, Min
Chen, Yineng
Thompson, John L. P.
Homma, Shunichi
Lip, Gregory Y. H.
,
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke
Article History
Received: 16 November 2023
Accepted: 16 January 2024
First Online: 23 February 2024
Declarations
:
: GFR reports consultancy for Boehringer Ingelheim and an educational grant from Anthos, outside the submitted work. No fees are directly received personally. KN received remunerations/fees for activities on behalf of Sanofi-Aventis, Eli Lilly, Novo Nordisk, Astra Zeneca, and Boehringer Ingelheim. MP is an investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement no 899871. GYHL has been a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Anthos. No fees are received personally. GYHL is a NIHR senior investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement no 899871. All other authors have nothing to declare.
: The study adhered to the principles of the Declaration of Helsinki; the study protocol was approved by the international review boards and ethics boards of participating centers, and written informed consent was provided by all patients. The trial was registered at ClinicalTrials.gov (NCT00041938).